Bedrocan Receives Health Canada Approval to Sell Domestically Produced Medical Cannabis

Bedrocan Cannabis Corp. (BED.V) (“the Company” or “Bedrocan”) announced today that it has received a license amendment from Health Canada allowing for the sale of the Company’s domestically produced medical cannabis. Bedrocan has been growing six proprietary genetic strains of standardized cannabis at... more →
Posted in: Press

Update On Medical Marijuana: Bedrocan Merges With MMPR As Majority

The move will also bring down base costs, help the company greatly expand its patient base, and lock down supply; an important benefit, as Bedrocan currently supplies much of Europe with its medicinal cannabis and could only spare so much for Canadians previously. Approval of their facility has been the sole missing piece of the... more →
Posted in: News

BreedIT and Seach Leverage Designer Strains to Better Cure

The benefits of medical cannabis are becoming increasingly apparent as companies like GW Pharmaceuticals plc (GWPH) publish the results of the clinical trials for their cannabinoid-based medicines. For example, their Epidiolex has shown tremendous potential in treating Dravet and Lennox-Gastaut syndromes. The creation of protocols... more →
Posted in: Press

Bedrocan Cannabis Corp. Reaches $1 Million in Product Revenues

Bedrocan Cannabis Corp. (TSXV: BED) (“Bedrocan” or the “Company”) announced today that in its first nine months of operations, the Company reached an aggregate of $1 million in revenues, with more than 1,400 registered medicinal cannabis patients. The revenue and patient figures were achieved from first product... more →
Posted in: Press
1 2